Please use this identifier to cite or link to this item: https://dora.health.qld.gov.au/qldresearchjspui/handle/1/2176
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHeussler, Helenen
dc.contributor.authorMitchell, M. D.en
dc.contributor.authorKwan Cheung, K. A.en
dc.date.accessioned2022-11-07T23:28:48Z-
dc.date.available2022-11-07T23:28:48Z-
dc.date.issued2021en
dc.identifier.citation12 , 2021en
dc.identifier.otherRISen
dc.identifier.urihttp://dora.health.qld.gov.au/qldresearchjspui/handle/1/2176-
dc.description.abstractNeurodevelopmental and neuropsychiatric disorders (such as autism spectrum disorder) have broad health implications for children, with no definitive cure for the vast majority of them. However, recently medicinal cannabis has been successfully trialled as a treatment to manage many of the patients' symptoms and improve quality of life. The cannabinoid cannabidiol, in particular, has been reported to be safe and well-tolerated with a plethora of anticonvulsant, anxiolytic and anti-inflammatory properties. Lately, the current consensus is that the endocannabinoid system is a crucial factor in neural development and health; research has found evidence that there are a multitude of signalling pathways involving neurotransmitters and the endocannabinoid system by which cannabinoids could potentially exert their therapeutic effects. A better understanding of the cannabinoids' mechanisms of action should lead to improved treatments for neurodevelopmental disorders.L6351842242021-06-10 <br />2021-06-16 <br />en
dc.language.isoenen
dc.relation.ispartofFrontiers in Psychiatryen
dc.titleCannabidiol and Neurodevelopmental Disorders in Childrenen
dc.typeArticleen
dc.identifier.doi10.3389/fpsyt.2021.643442en
dc.subject.keywordscentral nervous systemen
dc.subject.keywordsdepressionen
dc.subject.keywordsdrug efficacyen
dc.subject.keywordsdrug mechanismen
dc.subject.keywordsdrug resistant epilepsyen
dc.subject.keywordsendocannabinoid systemen
dc.subject.keywordsepilepsyen
dc.subject.keywordsfragile X syndromeen
dc.subject.keywordshumanen
dc.subject.keywordscannabinoid 2 receptoren
dc.subject.keywordsnervous system inflammationen
dc.subject.keywordsneurotransmissionen
dc.subject.keywordsnonhumanen
dc.subject.keywordsreviewen
dc.subject.keywordsschizophreniaen
dc.subject.keywordssleep disorderen
dc.subject.keywordscannabidiolcannabinoid 1 receptoren
dc.subject.keywordsmental diseaseen
dc.subject.keywordslipoxygenaseen
dc.subject.keywordsanxiety disorderen
dc.subject.keywordsautismen
dc.relation.urlhttps://www.embase.com/search/results?subaction=viewrecord&id=L635184224&from=exporthttp://dx.doi.org/10.3389/fpsyt.2021.643442 |en
dc.identifier.risid956en
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.cerifentitytypePublications-
item.openairetypeArticle-
item.languageiso639-1en-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
Appears in Sites:Children's Health Queensland Publications
Queensland Health Publications
Show simple item record

Page view(s)

68
checked on May 8, 2025

Google ScholarTM

Check

Altmetric


Items in DORA are protected by copyright, with all rights reserved, unless otherwise indicated.